Why Alkermes spun out an oncology company, whose shares have plummeted

The new company’s CEO says operating it separately allows for a more focused approach. Plus, it’s no longer competing with the rest of Alkermes, which currently has multiple neuroscience drugs in its pipeline, for money or talent.